Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: eptifibatide Clear all
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

NCT01977456
View directory record Official record
Conditions
Stroke, Brain Infarction
Interventions
Eptifibatide
Drug
Lead sponsor
Arthur Pancioli
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Edgewood, Kentucky • Florence, Kentucky • Fort Thomas, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional

Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

NCT00250991
View directory record Official record
Conditions
Stroke
Interventions
activase, integrilin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Sep 2, 2026, 4:43 PM EDT
Not listed Phase 1Phase 2 Interventional

Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic

NCT05415150
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Thrombolytic Agent
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 2, 2026, 4:43 PM EDT
Withdrawn No phase listed Observational

Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?

NCT01991366
View directory record Official record
Conditions
ST-elevation Myocardial Infarction, Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

NCT01863134
View directory record Official record
Conditions
Non ST Elevation Myocardial Infarction
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
Medical University of Silesia
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 2, 2026, 4:43 PM EDT
Not listed Phase 4 Interventional

Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin

NCT00370045
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bivalirudin with and without eptifibatide
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2006 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

NCT01522417
View directory record Official record
Conditions
Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
Interventions
Short Tirofiban, Eptifibatide, Long Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
13
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

NCT00061373
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Aspirin, tinzaparin sodium, eptifibatide
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

NCT01076764
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
13,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Phase 3 Interventional

Eptifibatide and ST Segment Resolution Following Primary PCI

NCT00812435
View directory record Official record
Conditions
Myocardial Infarction
Interventions
eptifibitide
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

NCT02925923
View directory record Official record
Conditions
Acute Coronary Syndrome, Angina, Unstable
Interventions
Ticagrelor, Eptifibatide, Clopidogrel
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

NCT01919723
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Eptifibatide
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

NCT00317395
View directory record Official record
Conditions
Coronary Disease
Interventions
Otamixaban (XRP0673), unfractionated heparin, eptifibatide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Phase 4 Interventional

Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

NCT00289601
View directory record Official record
Conditions
Angioplasty
Interventions
eptifibatide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2007 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

NCT00719914
View directory record Official record
Conditions
ST-Elevation Myocardial Infarction
Interventions
eptifibatide, normal saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Ormond Beach, Florida • Rochester, Michigan • Mansfield, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2012 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

NCT01103440
View directory record Official record
Conditions
Stable Angina
Interventions
Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Multi-arm Optimization of Stroke Thrombolysis

NCT03735979
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Argatroban, Eptifibatide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Fullerton, California • La Jolla, California + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

NCT00834899
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 2, 2026, 4:43 PM EDT